US OptionsDetailed Quotes
URGN250516P12500
- 1.76
- 0.000.00%
15min DelayClose May 2 16:00 ET
0.00High0.00Low
1.76Open1.76Pre Close0 Volume58 Open Interest12.50Strike Price0.00Turnover139.50%IV6.69%PremiumMay 16, 2025Expiry Date0.99Intrinsic Value100Multiplier12DDays to Expiry0.77Extrinsic Value100Contract SizeAmericanOptions Type-0.5767Delta0.1342Gamma6.54Leverage Ratio-0.0474Theta-0.0025Rho-3.77Eff Leverage0.0082Vega
UroGen Pharma Ltd Stock Discussion
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
Breakthrough Cancer Treatment JELMYTO Maintains 47.8-Month Response in Upper Tract Cancer Patients
Major Breakthrough: UroGen to Reveal 18-Month Cancer Treatment Data at Leading Urology Conference
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy
Breakthrough Bladder Cancer Treatment Achieves 83% Response Rate, FDA Decision Coming 2025
Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations
No comment yet